Sarepta Therapeutics Inc (SRPT)
121.90
+1.24
(+1.03%)
USD |
NASDAQ |
Dec 24, 16:00
Sarepta Therapeutics Cash from Investing (Quarterly): -128.82M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals Inc | -222.92M |
| Eli Lilly and Co | -4.005B |
| Alnylam Pharmaceuticals Inc | -30.25M |
| Catalyst Pharmaceuticals Inc | -0.259M |
| Vertex Pharmaceuticals Inc | -348.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -70.70M |
| Cash from Financing (Quarterly) | 13.76M |
| Free Cash Flow | -480.40M |
| Free Cash Flow Per Share (Quarterly) | -1.075 |
| Free Cash Flow to Equity (Quarterly) | -109.21M |
| Free Cash Flow to Firm (Quarterly) | -107.96M |
| Free Cash Flow Yield | -3.92% |